BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,586,521 | -20.2% | 96,761 | -4.3% | 0.01% | 0.0% |
| Q2 2023 | $8,251,896 | +18.0% | 101,089 | +7.3% | 0.01% | 0.0% |
| Q1 2023 | $6,991,740 | +4.1% | 94,241 | +16.3% | 0.01% | 0.0% |
| Q4 2022 | $6,714,192 | -2.7% | 81,011 | +233.2% | 0.01% | 0.0% |
| Q3 2022 | $6,904,000 | +7.0% | 24,310 | +30.6% | 0.01% | 0.0% |
| Q2 2022 | $6,451,000 | -41.6% | 18,609 | -27.0% | 0.01% | -28.6% |
| Q1 2022 | $11,045,000 | -22.8% | 25,509 | -7.8% | 0.01% | -12.5% |
| Q4 2021 | $14,307,000 | -27.3% | 27,656 | -31.9% | 0.01% | -33.3% |
| Q3 2021 | $19,671,000 | +7.6% | 40,593 | -0.1% | 0.01% | +9.1% |
| Q2 2021 | $18,289,000 | +35.2% | 40,619 | +14.7% | 0.01% | +22.2% |
| Q1 2021 | $13,528,000 | +32.4% | 35,423 | +10.1% | 0.01% | +50.0% |
| Q4 2020 | $10,220,000 | +18.5% | 32,183 | -7.6% | 0.01% | 0.0% |
| Q3 2020 | $8,627,000 | +35.6% | 34,824 | +44.6% | 0.01% | +20.0% |
| Q2 2020 | $6,361,000 | -85.2% | 24,086 | -89.4% | 0.01% | -87.2% |
| Q1 2020 | $43,004,000 | +1105.3% | 226,791 | +1295.5% | 0.04% | +1200.0% |
| Q4 2019 | $3,568,000 | +95.4% | 16,252 | +74.2% | 0.00% | +200.0% |
| Q3 2019 | $1,826,000 | +130.8% | 9,332 | +145.9% | 0.00% | 0.0% |
| Q2 2019 | $791,000 | -38.7% | 3,795 | -41.6% | 0.00% | 0.0% |
| Q1 2019 | $1,290,000 | -39.8% | 6,498 | -56.1% | 0.00% | -50.0% |
| Q4 2018 | $2,143,000 | -3.1% | 14,814 | +36.7% | 0.00% | 0.0% |
| Q3 2018 | $2,212,000 | +78.7% | 10,836 | +29.5% | 0.00% | +100.0% |
| Q2 2018 | $1,238,000 | -76.0% | 8,369 | -75.5% | 0.00% | -75.0% |
| Q1 2018 | $5,154,000 | +735.3% | 34,122 | +616.1% | 0.00% | – |
| Q4 2017 | $617,000 | +10.4% | 4,765 | +3.0% | 0.00% | – |
| Q3 2017 | $559,000 | -21.2% | 4,627 | -23.4% | 0.00% | -100.0% |
| Q2 2017 | $709,000 | +57.2% | 6,039 | +36.0% | 0.00% | – |
| Q1 2017 | $451,000 | -6.2% | 4,439 | -5.2% | 0.00% | – |
| Q4 2016 | $481,000 | -74.2% | 4,682 | -72.5% | 0.00% | -100.0% |
| Q3 2016 | $1,863,000 | +217.9% | 17,014 | +227.1% | 0.00% | +100.0% |
| Q2 2016 | $586,000 | -20.3% | 5,201 | -33.1% | 0.00% | 0.0% |
| Q1 2016 | $735,000 | +63.0% | 7,774 | +55.1% | 0.00% | – |
| Q4 2015 | $451,000 | -34.5% | 5,011 | -32.8% | 0.00% | -100.0% |
| Q3 2015 | $689,000 | -32.2% | 7,452 | -27.8% | 0.00% | 0.0% |
| Q2 2015 | $1,016,000 | -4.2% | 10,322 | -2.4% | 0.00% | 0.0% |
| Q1 2015 | $1,061,000 | +12.5% | 10,576 | +3.5% | 0.00% | 0.0% |
| Q4 2014 | $943,000 | – | 10,218 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |